Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edesa Biotech Inc EDSA

Healthcare Biotechnology
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a... see more

Recent & Breaking News (NDAQ:EDSA)

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Accesswire May 11, 2023

Edesa Biotech to Participate in Swiss Biotech Day

Accesswire April 20, 2023

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Accesswire April 4, 2023

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Accesswire March 23, 2023

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Accesswire March 16, 2023

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Accesswire March 15, 2023

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Accesswire February 10, 2023

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Accesswire February 1, 2023

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Accesswire January 17, 2023

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Accesswire December 20, 2022

Edesa Biotech Reports Fiscal Year 2022 Results

Accesswire December 16, 2022

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Accesswire December 2, 2022

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Accesswire November 3, 2022

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Accesswire September 30, 2022

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Accesswire September 8, 2022

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Accesswire September 7, 2022

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

Accesswire August 12, 2022

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

Accesswire August 3, 2022

Edesa Biotech to Present at ARDS Drug Development Summit

Accesswire July 11, 2022

Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

Accesswire May 24, 2022